Can Chemotherapy Induced Cardiomyopathy Be Detected from Pretreatment Platelets to Lymphocytes Ratio?

Objective: In this study, we aimed to identify patients at risk of chemotherapy-induced cardiotoxicity with a simple method like platelet- to-lymphocyte ratio (PLR) before starting therapy. Method: A total of 65 breast cancer patients who completed anthracycline or adjuvant trastuzumab treatment were evaluated retrospectively. Serial PLR calculations, echocardiographic examinations, and cardiac markers before treatment and after follow-up period were analyzed. Cardiotoxicity was determined according to Cardiac Review and Evaluation Committee Criteria. Results: Patients were divided into two groups according to their baseline PLR levels as Group C—PLR < 119 and Group D—PLR120. The median follow-up of the study was 22.23 (12-42) months. Concomitant disease and baseline characteristics were similar in both groups. Symptomatic cardiotoxicity was not observed in both groups. Cardiotoxicity was occurred in one patient (2.3%) in Group C and in four patients (9.5%) in Group D (P ¼ .005). Average mean left ventricular ejection fraction loss from baseline was 10.7 6 7.0% in Group D vs 2.3 6 6.4% in Group C (P ¼ .008). Interpretation of cardiac markers that were present in nearly half of the patients revealed that serum hs-c-reactive protein and pro-brain natriu¨ retic peptide levels were significantly higher in patients who developed cardiotoxicity compared to who did not develop cardiotoxicity. PLR 120 had 99% sensitivity and 85% specificity in predicting cardiotoxicity. Conclusion: This study’s results showed that high PLR levels were associated with chemotherapy-induced cardiotoxicity. To our best knowledge, this is the first study, examining the impact of whole blood test on chemotherapy-induced cardiotoxicity before starting the therapy and allowing doctors plot a route for these risky patients.

PDF

___

1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics in 2016. CA Cancer J Clin. 2010;60:207-221.
2. Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in The Netherlands: Stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010;124:801-807. [CrossRef]
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. [CrossRef]
4. Barthe´ le´my P, Heitz D, Mathelin C, et al. Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol. 2011;79:196-204. [CrossRef]
5. Kiderlen M, de Glas NA, Bastiaannet E, et al. Impact of comorbidity on outcome of older breast cancer patients: A FOCUS cohort study. Breast Cancer Res Treat. 2014;145:185-192. [Cross- Ref]
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30. [CrossRef]
7. Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst. 2012;104:1293-1305. [CrossRef]
8. Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350. [CrossRef]
9. Balkan F, Usluog˘ ulları CA, U¨ c¸ler R, et al. Mean platelet volume (MPV): Could it be used as a predictive marker for gestational diabetes? Gaziantep Med J. 2014;20:123-125. [CrossRef]
10. Liu WY, Lin SG, Wang LR, et al. Platelet-to-lymphocyte ratio: A novel prognostic factor for prediction of 90-day outcomes in critically ill patients with diabetic ketoacidosis. Medicine (Baltimore). 2016;95:E2596. [CrossRef]
11. Karakurt A, Yıldız C. Predictive values of inflammatory cell ratios for complexity of coronary artery disease in patients with acute coronary syndrome. Int J Cardiovasc Acad. 2018;4:70-76. [CrossRef]
12. Tutog˘ lu A, Boyacı A, Kocatu¨ rk O¨ , et al. The relationship of carpal tunnel syndrome and mean platelet volume in geriatric patients. Gaziantep Med J. 2014;20:182. [CrossRef]
13. Uslu A, Zehir R, Alizade E, et al. Association of neutrophil to lymphocyte ratio with lower patency rates among patients with infrapopliteal arterial disease undergoing balloon angioplasty. Int J Cardiovasc Acad. 2018;4:90-95. [CrossRef]
14. Koc¸ _I, Karatas ZA, Mandollu E, et al. Importance of mean platelet volume in patients with chronic obstructive pulmonary disease. Gaziantep Med J. 2014;20:294-298. [CrossRef]
15. Yılmaz Coskun F, Sucu M, Aksoy N, et al. The neutrophil to lymphocyte ratio and mean platelet volume with Gensini score in patients with acute myocardial infarction patients. Gaziantep Med J. 2015;21:200-204. [CrossRef]
16. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-939. [CrossRef]
17. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25:1029-1036. [CrossRef]
18. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910-3916. [CrossRef]
19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. [CrossRef]
20. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820. [CrossRef]
21. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC. PACS 04 trial. J Clin Oncol. 2009;27:6129-6134. [CrossRef]
22. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 Years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet. 2013;382:1021-1028. [CrossRef]
23. Pivot X, Romieu G, Debled M, et al. 6 Months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial. Lancet Oncol. 2013;14:741-748. [CrossRef]
24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. [CrossRef]
25. Keten HS, Yıldırım F, O¨ lmez S, et al. Knowledge, attitudes and behavior about breast cancer in women presenting to early cancer diagnosis, screening and education Centre in Kahramanmaras, Turkey. Gaziantep Med J. 2014;20:212-216. [CrossRef]
26. O¨ zkan B, Eskiyurt R, O¨ ztas D. Evaluation of the effectiveness of web-based intervention for patients with breast cancer. Eur J Ther. 2018;24:72-76. [CrossRef]
27. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809-816. [CrossRef]
28. Wang DY, Okoye GD, Neilan TG, et al. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19:21.
29. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer. 2011;47:2633- 2641. [CrossRef]
30. Haydarog˘ lu S ahin H. Can the prognosis of diffuse large B-cell lymphoma be predicted by a simple CBC count? Eur J Ther. 2019;25:76-81.
31. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet: Lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204- 1212. [CrossRef]
32. Yurtdas M,O¨ zdemir M, Aladag˘ N. Investigation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and mean platelet volume in patients with compensated heart failure. JAREM. 2018;8(2):67-71.
33. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116. [CrossRef]
34. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375-1380. [CrossRef]